Related Experiment Video
Updated: May 5, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
Four-variable risk model in men and women with heart failure
Jennifer Chyu1, Gregg C Fonarow, Chi Hong Tseng
1Division of Cardiology, University of Washington, Seattle.
Insights
A simple risk model using four key variables accurately predicts outcomes in advanced heart failure patients, regardless of sex. This model is effective for both men and women with heart failure (HF).
Area of Science:
- Cardiology
- Clinical Decision Making
- Prognostic Modeling
Background:
- Risk stratification is crucial for heart failure (HF) management.
- Unique characteristics of women with HF necessitate evaluating prognostic factors.
- The accuracy of sex-specific risk models in advanced HF is not well-established.
Purpose of the Study:
- To investigate if sex-specific risk models improve risk prediction in advanced HF patients.
- To identify key prognostic factors for outcomes in men and women with advanced HF.
Main Methods:
- Analysis of 2255 advanced HF patients from UCLA, divided into derivation and validation cohorts.
- Cox regression analysis to identify predictors of death/urgent transplantation/ventricular assist device.
- Comparison of the UCLA model with the Seattle Heart Failure Model (SHFM) and Heart Failure Survival Score (HFSS).
Main Results:
- Women with HF were younger, had higher ejection fraction, and better event-free survival.
- B-type natriuretic peptide, peak oxygen consumption (pkVO2), NYHA class, and ACE inhibitor/ARB use were strong predictors in both sexes.
- The UCLA model demonstrated superior performance (c-index 0.791) compared to SHFM (0.758) and HFSS (0.607-0.625).
Conclusions:
- A simple risk model incorporating B-type natriuretic peptide, pkVO2, NYHA class, and ACE inhibitor/ARB use provides prognostic information in advanced HF.
- This four-variable model is effective for both men and women with advanced heart failure.
Background:
Risk stratification is an integral component of clinical decision making in heart failure (HF). Women with HF have unique characteristics compared with men, and it is unknown whether common prognostic factors are equally useful in both populations. We aimed to investigate whether sex-specific risk models are more accurate for risk prediction in patients with advanced HF.
Methods And Results:
Patients with advanced HF referred to University of California, Los Angeles (UCLA; n=2255), were stratified by sex into derivation (referred in 2000-2007) and validation (referred in 2008-2011) cohorts. Cox regression analysis was used to ascertain key variables predictive of the primary end point of death/urgent transplantation/ventricular assist device in the derivation cohorts and confirmed in the validation cohorts in men, women, and the total population. Women were younger, with higher ejection fraction and better event-free survival. Despite differences in baseline characteristics, the 4 strongest predictors of outcome in both women and men, as well as in the total cohort, were B-type natriuretic peptide, peak oxygen consumption by cardiopulmonary exercise testing (pkVO2), New York Heart Association (NYHA) classification, and use of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. In addition, the UCLA model performed better than the Seattle Heart Failure Model (SHFM) and the Heart Failure Survival Score (HFSS) in our cohort (c-indices of 0.791[UCLA] versus 0.758 [SHFM], 0.607 [noninvasive HFSS], and 0.625 [invasive HFSS]).
Conclusions:
A simple risk model assessing 4 clinical variables-B-type natriuretic peptide, pkVO2, NYHA, and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use-is well suited to provide prognostic information in both men and women with advanced HF.
Related Concept Videos
Heart Failure IV: Classification and Diagnostic Evaluation
Pathophysiology of Heart Failure
Heart Failure I: Introduction
Heart Failure III: Clinical Manifestations
Heart Failure II: Pathophysiology
Heart Failure V: Medical Management
